CEO Ian Read, who'll remain at the top of the Pfizer org chart, raised the prospect of a big split in 2013, and divided internal operations into three units in January of the following year.

Pfizer's New Chief Scientific Officer Charts R&D Vision For High And Low-Risk Investments Vandana Singh Tue, Dec 3, 2024, 1:52 PM3 min read In this article: PFE ...

It's been several years since Pfizer (NYSE: PFE) was in a position to consistently outperform the S&P 500 index. There are two words that explain why: patent cliff. The big pharma company simply ...

Goldman Sachs hosted a meeting with Pfizer Inc’s (NYSE:PFE) newly appointed Chief Scientific Officer Chris Boshoff (effective January 1, 2025). The analyst maintains the Buy rating with a price ...

It's been several years since Pfizer (PFE -0.17%) was in a position to consistently outperform the S&P 500 index. There are two words that explain why: patent cliff. The big pharma company simply ...

Goldman Sachs hosted a meeting with Pfizer Inc’s (NYSE:PFE) newly appointed Chief Scientific Officer Chris Boshoff (effective January 1, 2025). The analyst maintains the Buy rating with a price target ...

Pfizer's Chris Boshoff outlines plans to prioritize high-return projects, with a focus on obesity, Oncology, and oral GLP-1 therapies, amid Q3 growth.